Literature DB >> 19531663

A homogeneous fluorescent live-cell assay for measuring 7-transmembrane receptor activity and agonist functional selectivity through beta-arrestin recruitment.

Bonnie J Hanson1, Justin Wetter, Mark R Bercher, Leisha Kopp, Maya Fuerstenau-Sharp, Kevin L Vedvik, Thomas Zielinski, Chris Doucette, Pamela J Whitney, Chetana Revankar.   

Abstract

Seven-transmembrane (7TM) receptors play an essential role in the regulation of a wide variety of physiological processes, making them one of the top target classes for pharmaceuticals. 7TM receptor function is mediated and modulated through 2 primary processes: G-protein and beta-arrestin signaling. Classically, it has been recognized that these 2 processes can interact with one another during 7TM receptor desensitization, but it has more recently been recognized that these 2 processes can also act independently of one another and can activate parallel signaling pathways. As such, the methods used to interrogate 7TM receptor signaling, both from a biological and a pharmaceutical perspective, may need to be reevaluated and the question of whether functionally selective compounds (compounds that selectively activate one pathway over another) can be rationally developed must be raised. Although numerous high-throughput screening (HTS) compatible assays exist for studying second messengers arising from G-protein signaling, far fewer HTS compatible assays exist for studying beta-arrestin recruitment. The authors report on the Tango 7TM receptor assay technology, a high-throughput homogeneous assay method for monitoring beta-arrestin recruitment that uses a live-cell fluorescent readout. This assay format is broadly applicable to 7TM receptors, independent of G-protein coupling and, as such, has been used to produce assays for over 70 7TM receptor targets. The authors also show how flow cytometry can be used to select clones with desired pharmacological profiles and how an inducible expression system can increase the assay window for targets with high levels of constitutive activity. Finally, they demonstrate how the Tango system can be used in parallel with assays aimed at second-messenger signaling to enable functional selectivity studies.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531663     DOI: 10.1177/1087057109335260

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  14 in total

Review 1.  Seven transmembrane receptors as shapeshifting proteins: the impact of allosteric modulation and functional selectivity on new drug discovery.

Authors:  Terry Kenakin; Laurence J Miller
Journal:  Pharmacol Rev       Date:  2010-04-14       Impact factor: 25.468

Review 2.  On the cutting edge: protease-based methods for sensing and controlling cell biology.

Authors:  H Kay Chung; Michael Z Lin
Journal:  Nat Methods       Date:  2020-07-13       Impact factor: 28.547

Review 3.  Minireview: More than just a hammer: ligand "bias" and pharmaceutical discovery.

Authors:  Louis M Luttrell
Journal:  Mol Endocrinol       Date:  2014-01-16

Review 4.  Approaches for probing allosteric interactions at 7 transmembrane spanning receptors.

Authors:  Michael T Klein; Paige N Vinson; Colleen M Niswender
Journal:  Prog Mol Biol Transl Sci       Date:  2013       Impact factor: 3.622

5.  Seeking Ligand Bias: Assessing GPCR Coupling to Beta-Arrestins for Drug Discovery.

Authors:  Laura M Bohn; Patricia H McDonald
Journal:  Drug Discov Today Technol       Date:  2010

6.  Biased agonism.

Authors:  Terry Kenakin
Journal:  F1000 Biol Rep       Date:  2009-11-26

7.  Quantitative analysis of neuropeptide Y receptor association with beta-arrestin2 measured by bimolecular fluorescence complementation.

Authors:  L E Kilpatrick; S J Briddon; S J Hill; N D Holliday
Journal:  Br J Pharmacol       Date:  2010-04-28       Impact factor: 8.739

8.  Designing Functionally Selective Noncatechol Dopamine D1 Receptor Agonists with Potent In Vivo Antiparkinsonian Activity.

Authors:  Michael L Martini; Caroline Ray; Xufen Yu; Jing Liu; Vladimir M Pogorelov; William C Wetsel; Xi-Ping Huang; John D McCorvy; Marc G Caron; Jian Jin
Journal:  ACS Chem Neurosci       Date:  2019-08-20       Impact factor: 4.418

9.  Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells.

Authors:  Joseph Kim; M L Richard Yip; Xiaoming Shen; Hubert Li; Li-Yu Charlie Hsin; Samuel Labarge; Eileen L Heinrich; Wendy Lee; Jianming Lu; Nagarajan Vaidehi
Journal:  PLoS One       Date:  2012-02-03       Impact factor: 3.240

Review 10.  Tools for GPCR drug discovery.

Authors:  Ru Zhang; Xin Xie
Journal:  Acta Pharmacol Sin       Date:  2012-01-23       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.